The immunosuppressive activity of spergualin analogues, 15-deoxyspergualin and N-30, is presented. These compounds suppressed antibody formation and establishment of delayedtype hypersensitivity to sheep red blood cells (SRBC) in mice. Amongspergualin, 15-deoxyspergualin, and N-30, 1 5-deoxyspergualin was most effective in suppressing immuneresponses. It suppressed antibody formation against SRBCby spleen cell cultures in a dose-dependent fashion without reducing cell viability. The spergualins also suppressed the mixedlymphocyte culture reaction. Peritoneal exudate cells taken from mice given immunosuppressive doses of 15-deoxyspergualin were not reduced in their functions measured: Release of lysosomal enzymes and production of superoxide anions. 15-Deoxyspergualin and N-30 were markedly effective in prolonging skin graft in rats.
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In a previous paper, we reported that spergualin, an antitumor antibiotic, had immunosuppressive activity and was effective in prolonging skin grafts in rats0. From a study on spergualin analogues, 15-deoxyspergualin and N-30 were found to have stronger antitumor activity than spergualin itself2' 3). Wereport in this paper the immunosuppressive effects of 15-deoxyspergualin and N-30 in mice and their effect on skin allografts in rats.
Materials and Methods
Animals C3H/He, C57BL/6, BALB/c, and CDFX(BALB/c XDBA/2) female mice, 6 to 8 weeks old, were purchased from Charles River Japan Inc., Japan. Males or females of the F344 and SHRstrains of rats (8 weeks old) were also purchased from Charles River Japan Inc., Japan. They were maintained under special pathogen-free conditions at 23 ztl°C and 55d=5 % humidity. Spergualins Spergualin ((-)-(155)-l-amino-19-guanidinol l,15-dihydroxy-4,9,12-triazanonadecane-10,13-dione), 1 5-deoxyspergualin ((±)-l-ammo-19 -guanidino-l l-hydroxy-4,9,12 -triazanonadecane-10,1 3 -dione), and N-30 (10-{iV-[4-(4-guanidinophenyl)butanoyl]-L-seryl}-l ,5, 10-triazadecane) were prepared by Takara Shuzo Co., Ltd., according to the methods described previously2).
ImmuneResponses Antibody formation and delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC) in mice were examined by methods reported previously4^. 15-Deoxyspergualin and other spergualins f Deceased.
were injected intraperitoneally on the day of immunization or from 1 day after the immunization, daily for 3 days in experiments on antibody formation or 4 days in those on DTH.Antibody formation was assayed by counting the number of plaque-forming cells (PFC) in spleen cell populations 4 days after the immunization. Secondary response of antibody formation was examined by the method described earlier10. Mice were immunized with 105 SRBCand given 6.25 mg/kg of 15-deoxyspergualin from 1 day after the immunization, daily for 9 days. Twenty-one days after the primary immunization, a second immunization was performed by iv injection of 108 SRBC,and 4 days thereafter the numberof PFCin the spleen was determined. The eliciting injection for the DTHresponses was performed 4 days after the immunization, and the response was determined by measuring footpad thickness 24 hours later.
Antibody formation to SRBCin spleen cell cultures was performed according to a modification of the method reported previously5). Spleen cells (1 x 107 cells/ml) taken from normal CDFi mice were cultured in Nunclon multi dish 24 dishes (Nunc. Nihon Inter Med. Co., Ltd., Tokyo) with or without various concentrations of 15-deoxyspergualin in mediumcontaining SRBC,and 4 days thereafter antibody formation in the cultures was determined by counting the number of PFC.
Mixed Lymphocyte Culture (MLC).Reaction MLCreaction was tested by a. commonlyused method3). Spleen cells taken from C3H/Hemice (H-2k) used as the responder were mixed with stimulator spleen cells taken from BALB/c(H-2d); the stimulator cells had been previously incubated with 50 jug/ml of mitomycin C (MMC) (Kyowa Hakko Kogyo Co., Ltd., Tokyo) at 37°C for 20 minutes. The mixed spleen cells were cultured with or without drugs in medium containing 10% fetal calf serum (FCS) (GIBCO, Grand Island, N.Y.) at 37°C for 5 days in 5%CO2in air and [3H]thymidine was added 16 hours before the assay. MLCreaction was determined by measuring the incorporation of [3H]thymidine into the cultured cells.
Macrophage Functions
Influence of 15-deoxyspergualin on the release of phorbol myristate acetate (PMA)-induced superoxide anion from peritoneal exudate cells was examined according to the method reported by Kitagawa and Johnston6). Mice were injected with 15-deoxyspergualin daily for 3 days and peritoneal exudate cells (PEC) were then taken from these mice. PEC were incubated with PMAfor 1 hour and the superoxide anion content of the supernatant was determined by measuring reduction of cytochrome C. The influence of 15-deoxyspergualin on release of lysosomal enzymesfrom macrophageswas examined according to the method reported by Hashimoto et alP. PECwere taken from mice given 15-deoxyspergualin and incubated with /?-nitrophenyl-/5-D-glucuronide for determination of -glucuronidase or^-nitrophenyl phosphate disodium for that of acid phosphatase. The activity of these enzymes was determined by measuring ODat 420 nmand was expressed the difference of CD( x lO3). To test the influence of 15-deoxyspergualin on activated macrophages, zymosan was used for activation of macrophages. Mice were injected with 2 mg of zymosan 4 days before the assay, and 1 day thereafter were given 15-deoxyspergualin daily for 3 days; then activities of PECwere examined.
Statistical Analysis Statistical significance was determined by Student's t-test analysis.
Results
Suppression of Antibody Formation and of DTHResponses to SRBCin Mice Spergualin and its synthetic analogues 15-deoxyspergualin and N-30 were injected into mice from the day of immunization daily for 4 days. As shown in Fig. 1 , each compound had a suppressive effect on both humoral and cellular immune responses in a dose-dependent manner.
Since amongthese spergualins, 1 5-deoxyspergualin was the most immunosuppressive, thereafter, 
the effect of 15-deoxyspergualin on antibody production and DTHresponse wasexamined. As shown in Fig. 2 , the daily injection of 15-deoxyspergualin at 0.4 to 25 mg/kg after immunization suppressed antibody production significantly (Fig. 2) . The injection of 1 5-deoxyspergualin after primary immunization suppressed the secondary antibody production (Table 1) . In this experiment, the daily injection of 15-deoxyspergualin did not affect spleen weight of mice in any group.
The suppressive effect of 15-deoxyspergualin against DTHis shown in Fig. 3 . The injection of 15-deoxyspergualin into mice at 1.6 to 25 mg/kg/day for 4 consecutive days from 1 day after the immunization suppressed the DTHresponse markedly. The response was enhanced slightly by the injection of 0.1 mg/kg/day, whereas doses lower than 0.1 mg/kg did not show any effect.
Suppression of Primary Antibody Formation to SRBC by 15-Deoxyspergualin
In Vitro Antibody formation against SRBCby spleen cell cultures in medium containing 10% FCS was suppressed by the addition of 15-deoxyspergualin to the cultures. As shown in Fig. 4 , the addition of 15-deoxyspergualin at the start of cultures reduced the number of PFC dose-dependently. Antibody This experiment was done by same method as described in Fig. 1 (A This experiment was performed by same method as described in Fig. 1 (B formation in vitro was suppressed significantly at more than 0.8^g/ml. It should be noted that in this experiment, the addition of 1 5-deoxyspergualin, even at 10^g/ml, did not affect cell viability.
Suppression of MLCReaction The influence of spergualins on the allogeneic MLCreaction was tested. As shown in Fig. 5 , each spergualins inhibited the MLCreaction in a dose-dependent manner, and N-30 and 1 5-deoxyspergualin showed stronger inhibitory activity than spergualin.
Influence of 1 5-Deoxyspergualin on PEC Among these spergualins, because of its strongest immunosuppressiveactivity, weexaminedthe action of 15-deoxyspergualin on macrophages using PECtaken from mice given immunosuppressive Results are mean value (±SD) of 5 mice.
doses of 15-deoxyspergualin. A single injection of 15-deoxyspergualin at 1.6~25 mg/kg did not result in any changes in the PEC functions measured, i.e., release of lysosomal enzymes and PMAinduced superoxide anion formation (data not shown). The influence of 15-deoxyspergualin on zymosan-activated macrophages was examined. Mice were given zymosanonce, 4 days before the assay, and given 15-deoxyspergualin daily for 3 days after the injection of zymosan. As shown in Table 2 , the daily injection of 15-deoxyspergualin neither suppressed nor enhanced functions of normal and zymosan-activated peritoneal exudate cells, although zymosan enhanced the release of lysosomal enzymes and of PMA-induced superoxide anions. Effect on Skin Allograft in Rats As we have already reported the effect of spergualin on rat skin allografti:>, in this report the effect of 15-deoxyspergualin on skin allografts in rats was examined. Tail skin taken from SHRrats was grafted onto the abdomen of F344 rats and each compound was injected intraperitoneally from 1 day after the graft daily for 10 days. As shown in Table 3 , each of the spergualin analogues at 3.1 to 12.5 mg/kg/day prolonged markedly the skin graft in a dose-dependent manner, though the effect of 15-deoxyspergualin was superior to that of N-30. 15-Deoxyspergualin injected every other day was also effective in prolonging skin grafts (Table 4) . By this schedule of injections skin grafts were prolonged more than 30 days at higher doses, such as 6.3 to 25 mg/kg.
Discussion
The immunosuppressive effects of spergualin analogues, 1 5-deoxyspergualin and N-30, were presented in this report. These compounds suppressed humoral and cell-mediated immune responses in a dose-dependent manner. Amongthem, 15-deoxyspergualin had the strongest immunosuppressive activity as well as strongest antitumor activity3). 15-Deoxyspergualin suppressed the DTHresponse at more than 1.6 mg/kg/day; and antibody formation, at more than 0.4 mg/kg/day. It also suppressed the secondary antibody formation by daily injection for 10 days after the primary immuni- Antibody formation by spleen cell cultures and the MLCresponse were also suppressed by 15-deoxyspergualin. The suppression of antibody formation in vitro by 15-deoxyspergualin did not change the total number of viable cells in cultures. As mentioned above, the daily administration of 15-deoxyspergualin suppressed immuneresponses markedly. However, various functions of peritoneal macrophages taken from mice given the immunosuppressive dose of 15-deoxyspergualin by daily injection were not affected. Moreover, as reported previously, spergualin and 15-deoxyspergualin enhanced interleukin 2 (IL-2) production in MLC; and even at high concentrations such as 100^g/ml, IL-2 production was not reduced3). The mechanism of action of 15-deoxyspergualin in suppressing immune responsesis nowunderstudy.
15-Deoxyspergualin and N-30 were markedly effective in prolonging skin allografts in rats, and the effect of 15-deoxyspergualin was superior to that of N-30 and spergualin. The prolongation of allografts by 15-deoxyspergualin was dependent on dose and schedule of administration. These compounds will be useful for transplantation of organs and for treatment of various immunologic diseases.
